ZYDUSLIFE

Zydus Lifesciences Share Price Zydus Lifesciences

₹1,007.35
7.65 (0.77%)
  • Advice
  • Hold
28 March, 2024 17:58 BSE: 532321 NSE: ZYDUSLIFEISIN: INE010B01027

Start SIP in Zydus Lifesciences

Start SIP

Zydus Lifesciences Performance

Day Range

  • Low 985
  • High 1,021
₹ 1,007

52 Week Range

  • Low 478
  • High 1,028
₹ 1,007
  • Open Price993
  • Previous Close1,000
  • Volume1873843

Zydus Lifesciences Share Price

  • Over 1 Month 6.84%
  • Over 3 Month 46.28%
  • Over 6 Month 66.46%
  • Over 1 Year 109.04%

Zydus Lifesciences Key Statistics

P/E Ratio 34.3
PEG Ratio 0.8
Market Cap Cr 101,964
Price to Book Ratio 5.2
EPS 16
Dividend 0.6
Relative Strength Index 64.94
Money Flow Index 57.89
MACD Signal 37.47
Average True Range 28.56
Zydus Lifesciences Financials
IndicatorDec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 2,3712,1592,9562,437
Operating Expenses Qtr Cr 1,6721,5101,8151,807
Operating Profit Qtr Cr 6996491,141773
Depreciation Qtr Cr 128125121120
Interest Qtr Cr 104919085
Tax Qtr Cr 124163232124
Net Profit Qtr Cr 450805781491
IndicatorMar 2023
Total Revenue Annual Cr 9,280
Operating Expenses Annual Cr 6,277
Operating Profit Annual in Cr 2,454
Depreciation Cr 489
Interest Annual Cr 278
Tax Annual Cr 503
Net Profit Annual Cr 1,529
IndicatorMar 2023
Cash from Operating Activity Annual Cr 1,078
Cash from Investing Activity Annual Cr -1,960
Cash from Financing Annual Activity Cr 827
Net Cash Flow Annual Cr -55
IndicatorMar 2023
Total ShareHolders Funds Annual Cr 13,639
Fixed Assets Annual Cr 4,923
Total Non Current Assets Annual Cr 13,405
Total Current Assets Annual Cr 7,158
Total Assets Annual Cr 20,564
IndicatorMar 2023
Book Value Per Share Annual Rs 135
ROE Annual % 11
ROCE Annual % 14
Total Debt to Total Equity Annual -
EBDIT Annual Margin % 34
IndicatorDec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 4,5054,3695,1404,853
Operating Expenses Qtr Cr 3,4033,2233,6343,755
Operating Profit Qtr Cr 1,1021,1461,5051,256
Depreciation Qtr Cr 195184180179
Interest Qtr Cr 2091828
Tax Qtr Cr 214226216137
Net Profit Qtr Cr 7908011,087297
IndicatorMar 2023
Total Revenue Annual Cr 17,424
Operating Expenses Annual Cr 13,378
Operating Profit Annual in Cr 3,860
Depreciation Cr 723
Interest Annual Cr 130
Tax Annual Cr 588
Net Profit Annual Cr 1,960
IndicatorMar 2023
Cash from Operating Activity Annual Cr 2,689
Cash from Investing Activity Annual Cr 1,171
Cash from Financing Annual Activity Cr -4,400
Net Cash Flow Annual Cr -540
IndicatorMar 2023
Total ShareHolders Funds Annual Cr 17,516
Fixed Assets Annual Cr 7,917
Total Non Current Assets Annual Cr 15,740
Total Current Assets Annual Cr 10,016
Total Assets Annual Cr 25,756
IndicatorMar 2023
Book Value Per Share Annual Rs 195
ROE Annual % 11
ROCE Annual % 16
Total Debt to Total Equity Annual -
EBDIT Annual Margin % 23

Zydus Lifesciences Technicals

EMA & SMA

Current Price
₹1,007.35
7.65 (0.77%)
pointer
  • Bullish Moving Average
  • ___
  • 16
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • ₹966.72
  • 50 Day
  • ₹890.15
  • 100 Day
  • ₹804.56
  • 200 Day
  • ₹710.43
  • 20 Day
  • ₹971.62
  • 50 Day
  • ₹874.12
  • 100 Day
  • ₹765.18
  • 200 Day
  • ₹685.02

Zydus Lifesciences Resistance and Support

PIVOT
₹1,008.57
Resistance
First Resistance 1,018.88
Second Resistance 1,038.07
Third Resistance 1,048.38
RSI 64.94
MFI 57.89
MACD Single Line 38.36
MACD 34.75
Support
First Resistance 989.38
Second Resistance 979.07
Third Resistance 959.88

Zydus Lifesciences Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 1,850,037 91,169,823 49.28
Week 1,445,289 75,574,149 52.29
1 Month 1,202,854 55,668,101 46.28
6 Month 1,378,535 60,848,536 44.14

Zydus Lifesciences Result Highlights

Zydus Lifesciences Synopsis

NSE-Medical-Generic Drugs

Zydus Lifesciences is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 8731.60 Cr. and Equity Capital is Rs. 101.20 Cr. for the Year ended 31/03/2023. Zydus Lifesciences Ltd. is a Public Limited Listed company incorporated on 15/05/1995 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1995PLC025878 and registration number is 025878.
Market Cap 102,309
Sales 10,066
Shares in Float 25.31
No of funds 349
Yield 0.6
Book Value 7.42
U/D Vol ratio 3.4
LTDebt / Equity 28
Alpha 0.23
Beta 0.52

Zydus Lifesciences

Owner NameDec-23Sep-23Jun-23Mar-23
Promoters 74.98%74.98%74.98%74.98%
Mutual Funds 6.99%5.94%5.8%5.59%
Insurance Companies 5.8%6.86%7.43%7.67%
Foreign Portfolio Investors 4.99%4.85%4.04%3.42%
Financial Institutions/ Banks 0.01%
Individual Investors 5.6%5.66%5.97%6.42%
Others 1.63%1.71%1.78%1.92%

Zydus Lifesciences Management

Name Designation
Mr. Pankaj R Patel Chairman
Dr. Sharvil P Patel Managing Director
Mr. Ganesh N Nayak Executive Director
Mr. Bhadresh K Shah Independent Director
Mr. Mukesh M Patel Non Executive Director
Mr. Nitin R Desai Independent Director
Ms. Dharmishtaben N Raval Independent Woman Director
Ms. Apurva S Diwanji Independent Director
Mrs. Upasana Konidela Independent Woman Director
Mr. Monappa Arun Akhil Independent Director

Zydus Lifesciences Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Zydus Lifesciences Corporate Action

Date Purpose Remarks
2024-02-09 Quarterly Results & Buy Back of shares
2023-11-07 Quarterly Results
2023-08-11 Quarterly Results
2023-05-18 Audited Results & Final Dividend
2023-02-03 Quarterly Results
Date Purpose Remarks
2023-07-28 FINAL Rs.6.00 per share(600%)Final Dividend
2022-07-29 FINAL Rs.2.50 per share(250%)Final Dividend

About Zydus Lifesciences

Zydus Lifesciences Limited (Zydus) is one of India’s leading pharmaceutical companies, engaged in the formulation and marketing of pharmaceutical products. Zydus Group has a leadership position in several segments in its portfolio with brands that are market leaders in their respective categories. 

The Group has a strong presence across therapeutic segments including pain management, cardiovascular diseases, urology and anti-infectives. It also offers over-the-counter healthcare products. It sells medicines through retail pharmacies, hospitals, and clinics to customers all over India and exports to various countries worldwide. 

The Company is organized into three business verticals: Pharmaceuticals, Active Ingredients and Contract Manufacturing Services (CMS). It manufactures active ingredients for use in formulations manufactured by other pharmaceutical companies; distributes finished formulations; provides contract manufacturing services for branded drugs, and markets finished formulations under its brand names.

Business Verticals

Zydus Lifesciences has three business divisions. The largest division is pharmaceuticals, which includes oral solid dosage and injectables. The second division is hospital equipment and supplies. Finally, there is a medical education division that includes training programs for medical professionals in both rural and urban areas as well as retail stores selling over-the-counter products to consumers.  

In addition to these divisions, Zydus Lifesciences provides consulting services for companies looking to enter or expand their presence in India. These services include regulatory and market access assistance, drug registration services, strategic marketing support and distribution channel optimization.

 

Milestones

1995 - Cadila Healthcare Ltd, the flagship company of the Zydus Cadila Group, was founded.

1996 - It went public in July. They also formed a strategic alliance with Gulin Pharma of China and launched Falcigo, an anti-malarial segment, in India.

2000 - In May, the company acquired Recon Ltd's formulation business, to strengthen its position in the southern market.

2001 - Acquired German Remedies which was the largest M&A in the Indian Pharmaceutical sector at the time. The same year they formed a joint venture with US-based Onconova for collaborative research in the field of Oncogenomics.

2002 - In April, the company acquired Banyan Chemicals, a Vadodara-based company registered with the US Food and Drug Administration.

2003 - Zydus Group decided to merge German Remedies Ltd and Recon Healthcare Ltd with Cadila Healthcare Ltd

2004 - In November, the company formed a strategic alliance with the Zambon Group in Italy to explore new opportunities in contract manufacturing. The same year, the company signed a long-term strategic agreement with Boehringer Ingelheim India Ltd, a wholly-owned subsidiary of Boehringer Ingelheim (BI), to manufacture and market BI's products in India.

2005 - The company formed a strategic alliance with Mallinckrodt Pharmaceuticals Generics, a Tyco Healthcare business unit, to market the company's product under a joint label. In the same year, the company formed a 50:50 joint venture with Australia's Mayne Pharma to produce generic injectable cytotoxic (anti-cancer) medicines as well as active pharmaceutical ingredients (API) for global markets.

2005-06 - During this fiscal year, the company formed a 50:50 joint venture with one of India's leading biotech companies, Bharat Serums and Vaccines Ltd (BSV), to develop, manufacture, and market a non-infringing and proprietary Novel Drug Delivery System (NDDS) of an approved anticancer product for global markets.

2006-07 - During this fiscal year, the company entered into a share purchase agreement to acquire a 97.95 per cent stake in Liva Healthcare Ltd, which manufactures and markets Formulations. They also built a brand-new green field facility for Solid Oral Dosage. They also built a Lyophilisation facility at the Moraiya plant with an annual capacity of 7.5 million dosages to serve both the Indian and international markets.

2007-08 - During this fiscal year, the company restructured its formulation division, Alidac, and launched two new subdivisions, Corza and Fortiza.
 

Zydus Lifesciences FAQs

What is Share Price of Zydus Lifesciences ?

Zydus Lifesciences share price is ₹1,007 As on 28 March, 2024 | 17:44

What is the Market Cap of Zydus Lifesciences ?

The Market Cap of Zydus Lifesciences is ₹101964.4 Cr As on 28 March, 2024 | 17:44

What is the P/E ratio of Zydus Lifesciences ?

The P/E ratio of Zydus Lifesciences is 34.3 As on 28 March, 2024 | 17:44

What is the PB ratio of Zydus Lifesciences ?

The PB ratio of Zydus Lifesciences is 5.2 As on 28 March, 2024 | 17:44

What were the company's most recent reported sales and net income?

Zydus Lifesciences Ltd. recorded a net income of INR 15,265.20  crores in FY22

What is the future of the company's shares?

Zydus Lifesciences Ltd. stock is a good option for long-term investment since the shares are ripe for buying right now.

How to buy shares of Zydus Lifesciences Ltd.?

The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.

Q2FY23